Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 4;11:787814. doi: 10.3389/fonc.2021.787814

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Zheng, Sun, Yi, Zhang, Wang, Lan, Zhang, Xian and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Dysregulated biological processes in Group 1 MM cases shorten survival and affect therapeutic responses. (A) Kaplan–Meier survival curves comparing the overall survival in MM cases with high or low expression of DNA repair/glycolysis/oxidative phosphorylation scores in the GSE24080 dataset. (B) Distribution of risk score, OS, survival status (red dots indicate dead; green dots indicate alive), and the three pathway scores’ heatmap in GSE24080. (C) Kaplan–Meier survival curves comparing the overall survival in MM cases with high- or low-risk score in the GSE24080 dataset. (D) The survival rate of MM patients with high/low DNA repair score treated with Bortezomib-based therapy. (E) The survival rate of MM patients with high/low glycolysis score treated with Bortezomib-based+Carfilzomib-based therapy.